Specific human leukocyte antigen class I genotypes predict prognosis in resected pancreatic adenocarcinoma: A retrospective cohort study

Qian Zhan, Lei Zhang, Chenlei Wen, Ying Yang, Yangbing Jin, Rende Mu, Zehui Zhang, Siyi Zou, Fanlu Li, Huaibo Sun, Jiabin Jin, Xiongxiong Lu, Junjie Xie, Dongfeng Cheng, Zhiwei Xu, Huan Chen, Beibei Mao, Jun Zhang, Jiancheng Wang, Xiaxing Deng, Chenghong Peng, Hongwei Li, Cen Jiang, Lin Lin, Henghui Zhang, Hao Chen, Baiyong ShenInternational Journal of Surgery 2023 · DOI

TL;DR

This study identifies a specific human leukocyte antigen class I (HLA-I) genotype, HLA-A02+B62+B44-, as a predictor of disease-free survival (DFS) in patients with resected pancreatic adenocarcinoma (PAAD), particularly in early-stage disease. This genotype is linked to a higher prevalence of KRAS and TP53 mutations, reduced HLA-A expression, and a less inflamed tumor microenvironment, suggesting a complex interplay between host genetics, tumor mutations, and immune response in determining patient outcomes.

What Problem Does This Paper Address?

Pancreatic adenocarcinoma (PAAD) is a highly lethal cancer with a dismal prognosis, even after surgical resection. While current prognostic markers like tumor size and lymph node involvement exist, they don't fully capture the variability in patient outcomes, especially for early-stage patients who can still experience rapid relapse. The authors hypothesize that the host's genetic makeup, specifically their human leukocyte antigen class I (HLA-I) genotype, could play a crucial role in predicting how well patients respond to surgery and their likelihood of recurrence. HLA-I molecules are critical for presenting tumor antigens to the immune system, and variations in these genes could influence the body's ability to recognize and fight cancer. This study aims to fill the gap by investigating whether specific HLA-I genotypes can serve as predictive biomarkers for postoperative outcomes in resected PAAD.

Methods

The study employed a multi-faceted approach:

  • Targeted Next-Generation Sequencing (NGS): DNA from matched blood cells and tumor tissues of 608 PAAD patients was sequenced to determine HLA-I (A, B, and C) genotypes and somatic mutations.
  • HLA-I Supertype Classification: HLA-A and B alleles were classified into "supertypes" based on their peptide-binding specificities, a method that groups alleles with similar functional characteristics.
  • Survival Analysis: Kaplan-Meier curves and multivariable Cox proportional-hazards regression were used to assess the association between HLA-I genotypes and disease-free survival (DFS) in a cohort of 226 patients who underwent radical resection.
  • RNA Sequencing: For a subset of patients with high-quality tumor samples, RNA sequencing was performed to examine gene expression profiles and investigate potential immunophenotypic differences.
  • Data Validation: Findings were validated using independent patient cohorts and public datasets (TCGA, ICGC) to confirm the prognostic significance of the identified HLA-I genotype and its associated molecular features.

Datasets

  • Discovery Cohort: 608 Chinese PAAD patients diagnosed pathologically, collected between March 2018 and April 2020.
  • Survival Analysis Cohort: 226 patients from the discovery cohort who underwent radical pancreatectomy (RO). This cohort included 185 early-stage (I-II) patients.
  • Independent Validation Cohorts:
    • LTS5 cohort: 42 stage I-II PAAD patients with radical resection who survived over 5 years post-surgery.
  • ER6 cohort: 78 early-stage PAAD patients who relapsed within 6 months post-surgery.
  • Public Datasets: TCGA (The Cancer Genome Atlas) and ICGC (International Cancer Genome Consortium) PAAD datasets were used for validation, focusing on survival outcomes and gene mutation data.

Key Insights and Ideas

  • HLA-I Genotype as a Prognostic Indicator: The study highlights that specific HLA-I genotypes are not just passive players but actively influence patient outcomes in PAAD. The combination HLA-A02+B62+B44- emerged as a significant predictor of worse DFS.
  • Stage-Specific Impact: The prognostic value of the HLA-A02+B62+B44- genotype was particularly pronounced in early-stage (I-II) PAAD patients, suggesting that the immune system's interaction with the tumor is more critical in the initial phases of the disease.
  • Molecular Underpinnings: The research delves into the "why" behind the observed associations, linking the unfavorable HLA-I genotype to:
  • Enriched Driver Mutations: A higher prevalence of KRAS G12D and TP53 mutations, known drivers of PAAD progression.
  • Reduced HLA-A Expression: Lower expression of HLA-A molecules in tumor cells, which could impair antigen presentation and immune surveillance.
  • Immune Microenvironment Alterations: A less inflamed tumor microenvironment, characterized by decreased infiltration of T cells.
  • The "Indicator" Concept: The study proposes that the co-occurrence of KRAS G12D and TP53 mutations can serve as a "derived genomic indicator" for the unfavorable HLA-I genotype, allowing for validation in datasets lacking HLA-I genotyping.

Key Results

  • Patients with the HLA-A02+B62+B44- genotype had significantly shorter DFS (median 239 days) compared to those without it (median 410 days), with a hazard ratio (HR) of 1.65 (P=0.0189).
  • In early-stage (I-II) PAAD patients, the HLA-A02+B62+B44- genotype was associated with even shorter DFS (median 237 days vs. 427 days, HR=1.85, P=0.007).
  • Multivariable analysis confirmed that HLA-A02+B62+B44- was an independent predictor of inferior DFS in stage I-II PAAD patients (HR=1.85, P=0.014).
  • Patients with the HLA-A02+B62+B44- genotype showed a higher rate of KRAS G12D and TP53 mutations.
  • RNA sequencing revealed significantly lower HLA-A expression in tumor tissues of patients with the HLA-A02+B62+B44- genotype.
  • The study also observed decreased expression of Activated CD8 T cell and Type 1 T helper cell signatures in these patients.
  • Validation in public datasets showed that the co-occurrence of KRAS G12D and TP53 mutations was associated with worse overall survival in PAAD patients, mirroring the stage-specific impact observed for the HLA-I genotype.

Limitations and Future Work

  • Lack of Independent Cohort for Direct Validation: While public datasets were used for validation, the authors acknowledge the absence of an independent, resected PAAD cohort with comprehensive HLA-I genotyping and survival data for direct validation.
  • Limited RNA Sequencing Sample Size: RNA sequencing was performed on a subset of 44 patients, which might limit the generalizability of the immunophenotypic findings.
  • Absence of Protein Data: Protein data for tumor-infiltrating lymphocytes was not available, which could further elucidate the immune microenvironment.
  • Future Directions:
    • Multiplex Immunohistochemistry: This technique is suggested to further validate the associations between HLA-I genotypes and the tumor immune microenvironment.
  • Therapeutic Neoantigen Vaccines: The findings suggest that combining specific neoantigens with favorable HLA-I genotypes might be a promising avenue for developing effective therapeutic strategies.
  • Targeting TLR8 and TNFSF9: Given the observed alterations in TLR8 and TNFSF9 expression, these molecules could be potential targets for future cancer immunotherapies, especially in the context of specific HLA-I genotypes.
  • Broader Ethnic and Clinical Context: Further research is needed to explore the interplay of HLA-I genotypes, oncogenic alterations, and prognosis across diverse ethnic populations and in different clinical settings (e.g., neoadjuvant therapy).

Summary updated

Abstract

The current results suggest that a specific combination of germline HLA-A02/B62/B44 supertype, HLA-A02 + B62 + B44 - , was a potential predictor for DFS in early-stage PAAD patients after surgery.
BibTeX
@article{zhan2023specific,
  author = {Qian Zhan and Lei Zhang and Chenlei Wen and Ying Yang and Yangbing Jin and Rende Mu and Zehui Zhang and Siyi Zou and Fanlu Li and Huaibo Sun and Jiabin Jin and Xiongxiong Lu and Junjie Xie and Dongfeng Cheng and Zhiwei Xu and Huan Chen and Beibei Mao and Jun Zhang and Jiancheng Wang and Xiaxing Deng and Chenghong Peng and Hongwei Li and Cen Jiang and Lin Lin and Henghui Zhang and Hao Chen and Baiyong Shen},
  title = {{Specific human leukocyte antigen class I genotypes predict prognosis in resected pancreatic adenocarcinoma: A retrospective cohort study}},
  journal = {International Journal of Surgery},
  year = {2023},
  doi = {10.1097/js9.0000000000000264},
}
Figure